About

Sunbelt Research Group, LLC is dedicated to advancing women’s health and improving patient
outcomes through excellence in clinical research, with a special emphasis on Obstetrics and
Gynecology services. As a founder-led clinical research network spanning Alabama, Mississippi,
and Florida, we conduct high-quality Phase II–IV trials across multiple therapeutic areas — with
a strong focus on OB/GYN, endocrinology, and related women’s health indications.
Guided by over 26 years of leadership in clinical research, we partner with sponsors,
investigators, and healthcare providers to accelerate the development of innovative therapies in
women’s reproductive health, maternal care, gynecologic conditions, and beyond. We uphold the
highest standards of ICH/GCP and FDA compliance while delivering patient-centered research
that empowers women, supports families, and transforms healthcare in our communities.
Committed to strategic growth, operational excellence, and ethical integrity, Sunbelt Research
Group continues to expand access to cutting-edge clinical trials that address the unique needs of
women’s health.

Neil D. Stimpson, BA, CCRC, is a seasoned Clinical Research Executive and Founder of Sunbelt
Research Group, LLC, with over 26 years of distinguished leadership in building and managing
multi-state clinical trial networks. As Research Director, he has successfully scaled the
organization across Alabama, Mississippi, and Florida, partnering with independent
practitioners, multi-specialty clinics, and hospital systems to deliver high-quality Phase II–IV
clinical trials.

With deep expertise in business development, site activation, project management, and
regulatory compliance, Neil has overseen more than 100 clinical trials across diverse therapeutic
areas. He brings particular strength in women’s health, including Obstetrics and Gynecology
(OB/GYN), endocrinology, and related indications. His leadership has driven consistent 20%
annual network growth, managed multi-million-dollar budgets, and ensured rigorous adherence
to ICH/GCP, FDA, and IRB standards while maintaining exceptional data quality and patient
outcomes.